Wednesday's top analyst upgrades and downgrades included Akamai Technologies, Carlyle, Ford, General Motors, JD.com, Moderna, Netflix, Peloton Interactive, Raytheon Technologies, Target, Tesla and...
Tuesday's top analyst upgrades and downgrades included AIG, Atlassian, Chubb, Deere, Hecla Mining, ITT, Netflix, Roku, Splunk, Square, Tesla and Workday.
Kala Pharmaceuticals said that it had positive topline results from its late-stage clinical trial for the treatment of dry eye disease.
Tuesday’s top analyst upgrades, downgrades and initiations included CSX, Hess, McDonald’s, Netflix, Nike, Oracle, RingCentral, Starbucks, Tesla and VMware.
Monday's top analyst upgrades, downgrades and initiations included Alibaba, AT&T, Bank of America, BlackBerry, Boeing, Citigroup, Cloudflare, DocuSign, Lululemon Athletica, Marvell Technology,...
ImmunoGen shares dropped on Monday after the firm released data from its late-stage ovarian cancer study at the European Society for Medical Oncology (ESMO) 2019 Congress in Barcelona, Spain.
Two research firms have called for major upside ahead Aldeyra Therapeutics, even after the big pop in the stock on Wednesday.
The top analyst upgrades, downgrades and initiations seen on Thursday include Glaukos, Honeywell, Itau, MongoDB, 3M, PayPal, Salesforce.com, Tandem Diabetes Care, Vodafone and National Bank of Greece.
The top analyst upgrades, downgrades and other research calls from Monday include American Electric Power, American Water Works, BHP Billiton, Boeing, Costco, Crocs, Dollar General, McDonald's and...
The top analyst upgrades, downgrades and other research calls from Thursday include Booking Holdings, Borg Warner, Delphi, Pandora, Ralph Lauren and Southwest Airlines.
Tetraphase Pharmaceuticals saw its shares get cut in half on Wednesday after the firm provided an update on its late-stage clinical trial for the treatment of urinary tract infections.
The top analyst upgrades, downgrades and other research calls from Tuesday include Amgen, Caterpillar, Dollar General, Duke Energy, General Electric, Honeywell, 3M, Netflix and Sprint.
Axovant Sciences watched its shares practically get halved in Monday’s session after the firm provided an update from a few of its midstage clinical trials.
The tale of two biotechs appears to be playing out between Aimmune Therapeutics and DBV Technologies, not just for the companies but between analysts as well.
Marinus Pharmaceuticals saw its shares make a huge gain to kick off the week after the firm announced top-line results from its mid-stage study in patients with CDKL5 disorder.